SlideShare a Scribd company logo
1 of 42
Analysis and Interpretation: Overview ,[object Object],[object Object],[object Object],[object Object],[object Object]
Framework for synthesis ,[object Object],[object Object],[object Object],[object Object],[object Object]
Why Perform a Meta-analysis? ,[object Object],[object Object],[object Object],[object Object],[object Object]
More on Meta-analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]
When not Appropriate to do M/a ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Dichotomous Measures ,[object Object],[object Object],[object Object],[object Object]
Risk ratio (RR)  aka relative risk RR =   a / (a+b)  c / (c+d) Risk/ probability/ chance  of the occurrence of an event in treatment relative to control Intervention Control a+b=n I c+d=n C Event No event d c b a
Sample RR Calculation Death No death RR =   14/133  =  0.11  = 0.13 128/148  0.86 Drug 133 148 Placebo 20 128 119 14
Odds ratio (OR) Intervention Control No event Event OR =  a / b  c / d  Odds of an event occurring to it not occurring for treatment relative to control a+b=n I c+d=n C d c b a
Sample OR Calculation Death No death Drug Placebo 133 148 OR =   14/119  =  0.12  = 0.019 128/20  6.4 20 128 119 14
Interpreting (for intervention) Increased odds (harmful) Increased odds  (beneficial) OR>1 (6.4/0.12) Reduced odds (beneficial) Reduced odds (not beneficial) OR<1 (0.12/6.4) No difference No difference OR=1, RR=1 Increased risk (harmful) Increased risk  (beneficial) RR>1 (0.86/0.11) Reduced risk  (beneficial) Reduced risk (not beneficial) RR<1 (0.11/0.86) Bad outcome  (e.g. infection) Good outcome (e.g. remission)
RR vs. OR ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Closer Look at Odds RR = 0.11 / 0.86 = 0.13 ↑ A rate (11%) OR = 0.12 / 6.4  = 0.019 ↑ ~1:9 ↑ ~7:1
Absolute Effect Measures ,[object Object],[object Object]
Risk Difference (RD) Death No death Actual difference in  risk of events Placebo Drug 133 148 RD = 14/133 – 128/148 = 0.11 – 0.86 = - 0.75 20 128 119 14
Risk Difference (RD)  (continued) ,[object Object],[object Object],[object Object]
NNT ,[object Object],[object Object],[object Object],[object Object],[object Object]
Uncertainty ,[object Object],[object Object],[object Object],[object Object]
Which effect measure for meta-analysis? ,[object Object],[object Object],[object Object]
Meta-analysis in RevMan
Meta-analysis in RevMan  (continued) ,[object Object],[object Object]
Fixed vs Random Effects ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Fixed Effects Analysis in Picture View
Random Effects Analysis in Picture View
Random effects in RevMan 5 ←  DerSimonian and Laird  random effects model
Random effects in RevMan 5  (continued) ←  DerSimonian and Laird  random effects model
Sample Forest plot (RR) ,[object Object]
Meta-analysis for Continuous Data ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Mean Difference (MD) ,[object Object],[object Object]
Standardized Mean Difference (SMD) ,[object Object]
Heterogeneity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
    Clinical and Methodologic Heterogeneity  ,[object Object],[object Object],[object Object]
Statistical Heterogeneity ,[object Object],[object Object]
Q test ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
I 2  Statistic ,[object Object],[object Object],[object Object]
I 2  Statistic  (continued) * Importance of I 2  value depends on: ●  magnitude and direction of effects ●  strength of evidence of heterogeneity - Chi-squared P value, or - I 2  confidence interval Considerable heterogeneity*  75% to 100% May represent substantial heterogeneity* 50% to 90% May represent moderate heterogeneity* 30% to 60% Might not be important 0% to 40% Guide to Interpretation I 2  value
Sample Forest Plot:  Q and I 2
What to do with (Statistical) Heterogeneity ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
What to do with (Statistical) Heterogeneity ,[object Object],[object Object],[object Object],[object Object]
Subgroup and Meta-regression ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Subgroup Analysis
Sensitivity Analysis ,[object Object],[object Object],[object Object],[object Object],[object Object]

More Related Content

What's hot

Seminaar on meta analysis
Seminaar on meta analysisSeminaar on meta analysis
Seminaar on meta analysis
Preeti Rai
 
Malimu cross sectional studies.
Malimu cross sectional studies.Malimu cross sectional studies.
Malimu cross sectional studies.
Miharbi Ignasm
 
Study Designs_YL
Study Designs_YLStudy Designs_YL
Study Designs_YL
Yvonne Lee
 
Metanalysis Lecture
Metanalysis LectureMetanalysis Lecture
Metanalysis Lecture
drmomusa
 

What's hot (20)

Epidemiology Exercises
Epidemiology ExercisesEpidemiology Exercises
Epidemiology Exercises
 
Case Control Studies
Case Control StudiesCase Control Studies
Case Control Studies
 
Epidemiology Study Design
Epidemiology Study DesignEpidemiology Study Design
Epidemiology Study Design
 
Nested case control,
Nested case control,Nested case control,
Nested case control,
 
Seminar case control study
Seminar case control studySeminar case control study
Seminar case control study
 
Seminaar on meta analysis
Seminaar on meta analysisSeminaar on meta analysis
Seminaar on meta analysis
 
Case control study
Case control studyCase control study
Case control study
 
4. Calculate samplesize for cross-sectional studies
4. Calculate samplesize for cross-sectional studies4. Calculate samplesize for cross-sectional studies
4. Calculate samplesize for cross-sectional studies
 
Biases in epidemiology
Biases in epidemiologyBiases in epidemiology
Biases in epidemiology
 
Part 1 Survival Analysis
Part 1 Survival AnalysisPart 1 Survival Analysis
Part 1 Survival Analysis
 
unmatched case control studies
unmatched case control studiesunmatched case control studies
unmatched case control studies
 
Malimu cross sectional studies.
Malimu cross sectional studies.Malimu cross sectional studies.
Malimu cross sectional studies.
 
Assessment of Bias
Assessment of BiasAssessment of Bias
Assessment of Bias
 
Clinical prediction models
Clinical prediction modelsClinical prediction models
Clinical prediction models
 
Cross sectional study-dr.wah
Cross sectional study-dr.wahCross sectional study-dr.wah
Cross sectional study-dr.wah
 
Cross sectional study
Cross sectional studyCross sectional study
Cross sectional study
 
Study Designs_YL
Study Designs_YLStudy Designs_YL
Study Designs_YL
 
Epidemiology lecture 1 introduction
Epidemiology lecture 1 introductionEpidemiology lecture 1 introduction
Epidemiology lecture 1 introduction
 
History of epidemiology
History of epidemiologyHistory of epidemiology
History of epidemiology
 
Metanalysis Lecture
Metanalysis LectureMetanalysis Lecture
Metanalysis Lecture
 

Similar to Analysis and Interpretation

Baker esni handouts slides
Baker esni handouts slidesBaker esni handouts slides
Baker esni handouts slides
BartsMSBlog
 
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.pptIntroduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
AnnaMarieAndalRanill
 
2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final
Brian Lin
 
Importance of evidence
Importance of evidenceImportance of evidence
Importance of evidence
sahughes
 
Research methods 2 operationalization &amp; measurement
Research methods 2   operationalization &amp; measurementResearch methods 2   operationalization &amp; measurement
Research methods 2 operationalization &amp; measurement
attique1960
 
Quantitative_analysis.ppt
Quantitative_analysis.pptQuantitative_analysis.ppt
Quantitative_analysis.ppt
mousaderhem1
 

Similar to Analysis and Interpretation (20)

Statistics in meta analysis
Statistics in meta analysisStatistics in meta analysis
Statistics in meta analysis
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011
 
Biostatistics clinical research & trials
Biostatistics clinical research & trialsBiostatistics clinical research & trials
Biostatistics clinical research & trials
 
Baker esni handouts slides
Baker esni handouts slidesBaker esni handouts slides
Baker esni handouts slides
 
Baker esni handouts reading papers
Baker esni handouts reading papersBaker esni handouts reading papers
Baker esni handouts reading papers
 
Metaanalysis copy
Metaanalysis    copyMetaanalysis    copy
Metaanalysis copy
 
bio statistics for clinical research
bio statistics for clinical researchbio statistics for clinical research
bio statistics for clinical research
 
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.pptIntroduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
Introduction_klsfnsfsnfsgnkgni _to_meta-analysis.ppt
 
Sample Size Estimation and Statistical Test Selection
Sample Size Estimation  and Statistical Test SelectionSample Size Estimation  and Statistical Test Selection
Sample Size Estimation and Statistical Test Selection
 
Meta analysis with R
Meta analysis with RMeta analysis with R
Meta analysis with R
 
2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final2016 Symposium Poster - statistics - Final
2016 Symposium Poster - statistics - Final
 
Analytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational DataAnalytic Methods and Issues in CER from Observational Data
Analytic Methods and Issues in CER from Observational Data
 
Bgy5901
Bgy5901Bgy5901
Bgy5901
 
Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015Quantitative critical appraisal october 2015
Quantitative critical appraisal october 2015
 
Displaying your results
Displaying your resultsDisplaying your results
Displaying your results
 
Bias and validity
Bias and validityBias and validity
Bias and validity
 
Importance of evidence
Importance of evidenceImportance of evidence
Importance of evidence
 
Research methods 2 operationalization &amp; measurement
Research methods 2   operationalization &amp; measurementResearch methods 2   operationalization &amp; measurement
Research methods 2 operationalization &amp; measurement
 
Quantitative_analysis.ppt
Quantitative_analysis.pptQuantitative_analysis.ppt
Quantitative_analysis.ppt
 
Session1b.ppt
Session1b.pptSession1b.ppt
Session1b.ppt
 

More from Francisco J Grajales III

Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Francisco J Grajales III
 

More from Francisco J Grajales III (20)

Patient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharingPatient perspectives on (an)onymous data sharing
Patient perspectives on (an)onymous data sharing
 
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
Using Social Media in (Evidence-Based Emergency) Medicine: A Primer for Pract...
 
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare StudentsMulti-User Virtual Environments in Healthcare: A Primer for Healthcare Students
Multi-User Virtual Environments in Healthcare: A Primer for Healthcare Students
 
Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers Pianissisimo: A Primer on Communicating with Decision Makers
Pianissisimo: A Primer on Communicating with Decision Makers
 
Las TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas alláLas TIC y la Sanidad 2.0: Al infinito y mas allá
Las TIC y la Sanidad 2.0: Al infinito y mas allá
 
Panorama Internacional del eHealth
Panorama Internacional del eHealthPanorama Internacional del eHealth
Panorama Internacional del eHealth
 
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
To tweet or not to tweet? : Exploring the use of Social Media for [public] he...
 
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...Perceptions and attitudes toward virtual-reality medical training: The Ann My...
Perceptions and attitudes toward virtual-reality medical training: The Ann My...
 
Forumclinic Reshape 09
Forumclinic Reshape 09Forumclinic Reshape 09
Forumclinic Reshape 09
 
E-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica BoatengE-Government and E-Health Strategies by Mrs. Veronica Boateng
E-Government and E-Health Strategies by Mrs. Veronica Boateng
 
eHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in AfricaeHealth : the promise of ICT for improving health in Africa
eHealth : the promise of ICT for improving health in Africa
 
ICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-HealthICT Infrastructure in Africa and the uptake of e-Health
ICT Infrastructure in Africa and the uptake of e-Health
 
Electronic Health Records Global Perspectives
Electronic Health Records Global PerspectivesElectronic Health Records Global Perspectives
Electronic Health Records Global Perspectives
 
Interoperability Standards: The Key to Mobile Data
Interoperability Standards:The Key to Mobile DataInteroperability Standards:The Key to Mobile Data
Interoperability Standards: The Key to Mobile Data
 
Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...Public Health Informatics in Africa Examples from IDRC supported projects in ...
Public Health Informatics in Africa Examples from IDRC supported projects in ...
 
Role of standards, consumer education and media literacy
Role of standards, consumer education and media literacyRole of standards, consumer education and media literacy
Role of standards, consumer education and media literacy
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 
Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...Quality and safety of health information on the Internet: Who decides and ho...
Quality and safety of health information on the Internet: Who decides and ho...
 

Recently uploaded

+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
?#DUbAI#??##{{(☎️+971_581248768%)**%*]'#abortion pills for sale in dubai@
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Safe Software
 

Recently uploaded (20)

Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
Navigating the Deluge_ Dubai Floods and the Resilience of Dubai International...
 
Exploring Multimodal Embeddings with Milvus
Exploring Multimodal Embeddings with MilvusExploring Multimodal Embeddings with Milvus
Exploring Multimodal Embeddings with Milvus
 
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
Apidays New York 2024 - Passkeys: Developing APIs to enable passwordless auth...
 
Artificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : UncertaintyArtificial Intelligence Chap.5 : Uncertainty
Artificial Intelligence Chap.5 : Uncertainty
 
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
Apidays New York 2024 - The Good, the Bad and the Governed by David O'Neill, ...
 
presentation ICT roal in 21st century education
presentation ICT roal in 21st century educationpresentation ICT roal in 21st century education
presentation ICT roal in 21st century education
 
Strategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a FresherStrategies for Landing an Oracle DBA Job as a Fresher
Strategies for Landing an Oracle DBA Job as a Fresher
 
How to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected WorkerHow to Troubleshoot Apps for the Modern Connected Worker
How to Troubleshoot Apps for the Modern Connected Worker
 
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
Connector Corner: Accelerate revenue generation using UiPath API-centric busi...
 
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost SavingRepurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
Repurposing LNG terminals for Hydrogen Ammonia: Feasibility and Cost Saving
 
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
+971581248768>> SAFE AND ORIGINAL ABORTION PILLS FOR SALE IN DUBAI AND ABUDHA...
 
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
Biography Of Angeliki Cooney | Senior Vice President Life Sciences | Albany, ...
 
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, AdobeApidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
Apidays New York 2024 - Scaling API-first by Ian Reasor and Radu Cotescu, Adobe
 
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
DEV meet-up UiPath Document Understanding May 7 2024 AmsterdamDEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
DEV meet-up UiPath Document Understanding May 7 2024 Amsterdam
 
AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024AXA XL - Insurer Innovation Award Americas 2024
AXA XL - Insurer Innovation Award Americas 2024
 
DBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor PresentationDBX First Quarter 2024 Investor Presentation
DBX First Quarter 2024 Investor Presentation
 
Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...Apidays New York 2024 - The value of a flexible API Management solution for O...
Apidays New York 2024 - The value of a flexible API Management solution for O...
 
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
Emergent Methods: Multi-lingual narrative tracking in the news - real-time ex...
 
MS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectorsMS Copilot expands with MS Graph connectors
MS Copilot expands with MS Graph connectors
 
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers:  A Deep Dive into Serverless Spatial Data and FMECloud Frontiers:  A Deep Dive into Serverless Spatial Data and FME
Cloud Frontiers: A Deep Dive into Serverless Spatial Data and FME
 

Analysis and Interpretation

  • 1.
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. Risk ratio (RR) aka relative risk RR = a / (a+b) c / (c+d) Risk/ probability/ chance of the occurrence of an event in treatment relative to control Intervention Control a+b=n I c+d=n C Event No event d c b a
  • 8. Sample RR Calculation Death No death RR = 14/133 = 0.11 = 0.13 128/148 0.86 Drug 133 148 Placebo 20 128 119 14
  • 9. Odds ratio (OR) Intervention Control No event Event OR = a / b c / d Odds of an event occurring to it not occurring for treatment relative to control a+b=n I c+d=n C d c b a
  • 10. Sample OR Calculation Death No death Drug Placebo 133 148 OR = 14/119 = 0.12 = 0.019 128/20 6.4 20 128 119 14
  • 11. Interpreting (for intervention) Increased odds (harmful) Increased odds (beneficial) OR>1 (6.4/0.12) Reduced odds (beneficial) Reduced odds (not beneficial) OR<1 (0.12/6.4) No difference No difference OR=1, RR=1 Increased risk (harmful) Increased risk (beneficial) RR>1 (0.86/0.11) Reduced risk (beneficial) Reduced risk (not beneficial) RR<1 (0.11/0.86) Bad outcome (e.g. infection) Good outcome (e.g. remission)
  • 12.
  • 13. Closer Look at Odds RR = 0.11 / 0.86 = 0.13 ↑ A rate (11%) OR = 0.12 / 6.4 = 0.019 ↑ ~1:9 ↑ ~7:1
  • 14.
  • 15. Risk Difference (RD) Death No death Actual difference in risk of events Placebo Drug 133 148 RD = 14/133 – 128/148 = 0.11 – 0.86 = - 0.75 20 128 119 14
  • 16.
  • 17.
  • 18.
  • 19.
  • 21.
  • 22.
  • 23. Fixed Effects Analysis in Picture View
  • 24. Random Effects Analysis in Picture View
  • 25. Random effects in RevMan 5 ← DerSimonian and Laird random effects model
  • 26. Random effects in RevMan 5 (continued) ← DerSimonian and Laird random effects model
  • 27.
  • 28.
  • 29.
  • 30.
  • 31.
  • 32.
  • 33.
  • 34.
  • 35.
  • 36. I 2 Statistic (continued) * Importance of I 2 value depends on: ● magnitude and direction of effects ● strength of evidence of heterogeneity - Chi-squared P value, or - I 2 confidence interval Considerable heterogeneity* 75% to 100% May represent substantial heterogeneity* 50% to 90% May represent moderate heterogeneity* 30% to 60% Might not be important 0% to 40% Guide to Interpretation I 2 value
  • 37. Sample Forest Plot: Q and I 2
  • 38.
  • 39.
  • 40.
  • 42.